Aniracetam.
The anxiolytic racetam. Focus without anxiety. Claims to boost focus, memory, and creativity while reducing anxiety. It works on brain receptors involved in learning and mood.
Reviewed March 2026
- Category
- Nootropic
- Also filed under
- CognitionAnxietyCreativity
What Aniracetam is, and what it does.
- Does it work
- Probably not. The studies in healthy humans are sparse and unconvincing. Better to focus on things that actually work, like quality sleep.
- How much to take
- Standard dose is 750mg, once or twice a day. It's fat-soluble, so take it with a meal or some fish oil for better absorption.
- Time to feel it
- This one works dose by dose. Where something shifts, it turns up within an hour or two and fades the same day rather than building across weeks.
- The first dose
- You might feel a slight shift within an hour or two. A kind of calm focus. Or you might feel absolutely nothing. Don't expect a miracle.
- With regular use
- Unclear. The effects don't seem to build up over time. What you feel on day one is likely the best you'll get. Long-term safety is a question mark.
- How well tolerated
- Considered relatively safe in short-term studies. But it's sold as a 'supplement' while being an unapproved drug in the US. That's a gray area.
- How it feels
- Subtle. A mild anti-anxiety effect mixed with slightly easier brainstorming. Not a stimulant. You will not turn into the guy from 'Limitless'.
- The overlooked benefit
- It's fat soluble, so a dose with a meal that contains fat and a dose on an empty stomach aren't the same exposure. Timing with food matters more here than nudging the amount up.
750 to 1,500mg a day is where Aniracetam works.
Source: Nakamura & Tanaka Eur J Pharmacol 2001; nootropic community data
The proof, claim by claim.
These words describe the research, not the molecule's worth. Research strength is how much work stands behind one claim, and it is never a product score.
Based on 20 human trials with 55% consistency.
- Attention and working memory in healthy adultsNarrative review
- Positive allosteric modulation of AMPA glutamate receptorsIn vitro study
- Learning and memory measures in animal modelsAnimal study
- Calm behaviour measures in animal modelsAnimal study
- Cholinergic signalling alongside racetam dosingAnimal study
Questions people ask about Aniracetam.
- Is Aniracetam a stimulant?
- No. It's often described as having a calming, anti-anxiety effect. It won't feel like coffee or Adderall.
- Is it legal to buy?
- It's in a legal gray area in the US. It's not approved as a drug but is sold as a 'supplement'. It's a prescription drug in some parts of Europe.
- Can I take it every day?
- Some people do, but cycling (e.g., 5 days on, 2 days off) is common to keep effects noticeable. Long-term daily use hasn't been well-studied.
- Will it help me study?
- Maybe. Some users find it helps with creative thinking and connecting ideas, but for pure memorization, the evidence isn't strong.
- How long do the effects last?
- A few hours. It has a short half-life, so people often take it twice a day if they're using it.
- Is Aniracetam addictive?
- It's not considered physically addictive. Some people might become psychologically dependent on the feeling it gives them, like with any substance.
Why these belong in the same formula. Each row says what the basis is, from settled biochemistry through to a trial that measured the pair.
Racetams increase acetylcholine release and turnover at the synapse, which draws on the available choline pool. Alpha-GPC crosses into the brain and refills that pool, which is why the pairing is standard practice.
Acetylcholine is made from choline and acetyl-CoA by choline acetyltransferase, so higher turnover raises the substrate requirement. Supplying choline is the direct way to meet it.
Phosphatidylcholine feeds the same choline pool through membrane turnover rather than as free choline. It is the slower release form used in the same racetam pairing.
Huperzine A slows acetylcholinesterase so released acetylcholine lingers at the synapse, while the racetam raises release. The two push cholinergic tone in the same direction and stack additively.
Both are pyrrolidone nootropics acting on AMPA receptor modulation and membrane fluidity, with aniracetam the more lipophilic of the two. Combining them adds effect within one mechanism rather than covering a second one.
Noopept is a peptide analogue of the racetam family and raises the same cholinergic demand. Stacking the two increases the choline requirement rather than splitting it.
Lecithin supplies phosphatidylcholine as a food form choline reserve the brain draws on slowly. It is the low cost partner for racetam use.
Citicoline delivers choline plus cytidine, feeding both acetylcholine synthesis and phosphatidylcholine turnover in membranes. Racetams are described as facilitating cholinergic transmission, which draws on the available choline pool. Pairing a precursor with a facilitator is the standard stack rationale and rests on the biochemistry rather than on a trial of the combination.
Aniracetam is lipophilic and poorly water-soluble, so the amount absorbed depends on lipid being present in the gut at the same time. Medium-chain triglycerides provide that vehicle and are absorbed quickly themselves. Taking the compound dry on an empty stomach is the situation this pairing addresses.
A long-chain fatty acid load in the same meal supports micelle formation and lymphatic uptake of a lipophilic molecule, which is the ordinary handling for aniracetam. Separately, DHA is a major structural fatty acid of neuronal membranes where glutamate receptors sit. The absorption part is settled pharmacology; the membrane part is a mechanism statement rather than a measured combination effect.
L-theanine is a glutamate analogue with weak activity at glutamate receptors and is associated with increased alpha-band activity in electroencephalography studies. Aniracetam positively modulates AMPA-type glutamate receptors. The pairing is common in nootropic formulas on the logic that one adds excitatory facilitation and the other adds calm; the two have not been studied together.
Caffeine blocks adenosine receptors, which is a different entry point from AMPA receptor modulation. Stacks combine them for perceived alertness. No combination data exists, and stacking stimulant-adjacent compounds is where dose restraint matters most.
Phosphatidylserine is enriched on the inner leaflet of neuronal membranes and participates in signalling protein docking. Aniracetam's target, the AMPA receptor, is a membrane protein whose kinetics depend on its lipid environment. The rationale is structural and the pair has not been measured together in people.
Acetyl-L-carnitine carries an acetyl group that enters the mitochondrial acetyl-CoA pool, and acetyl-CoA is the acetyl donor for choline acetyltransferase. Pairing it with a cholinergic-facilitating racetam addresses the acetyl side of acetylcholine synthesis, where choline supplements address the other side. This is biochemistry, not a combination trial.
Coenzyme A is built from pantothenic acid, and acetyl-CoA is the obligatory acetyl donor for acetylcholine synthesis. Without adequate pantothenate no amount of supplemental choline produces acetylcholine. This makes it the quiet prerequisite in any cholinergic stack.
Magnesium sits in the NMDA receptor pore and blocks it in a voltage-dependent way, so it constrains one arm of glutamatergic signalling while AMPA receptors carry the fast component that aniracetam modulates. Adequate magnesium status is therefore part of the background against which any glutamatergic compound acts. The channel block is textbook; a benefit from combining them is not established.
Bacosides have been studied over weeks to months for effects on memory acquisition and retention, a slow-onset profile. Aniracetam is short-acting and lipophilic with a rapid onset. Formulas combine slow and fast components deliberately; the combination itself has not been tested.
Tyrosine is hydroxylated to L-DOPA and then decarboxylated to dopamine, so it supplies the catecholamine arm rather than the cholinergic or glutamatergic ones. Stacks add it for a different neurotransmitter system. Precursor supply matters most under depletion conditions, and the pair has not been studied together.
Ginkgo flavone glycosides and terpene lactones are associated with cerebral perfusion and platelet effects, an entirely different route from AMPA receptor modulation. The pairing is a product convention. Ginkgo's platelet effect is the interaction worth respecting in anyone on antiplatelet or anticoagulant therapy.
Taurine has weak agonist activity at glycine and GABA-A receptors and participates in osmoregulation in neural tissue. That places it on the inhibitory side of a balance whose excitatory side aniracetam touches. The pairing is speculative and belongs at Early.
Thiamine pyrophosphate is the cofactor for pyruvate dehydrogenase, the step that generates the acetyl-coenzyme A used in acetylcholine synthesis. Neuronal cholinergic output is therefore sensitive to thiamine status. The cofactor relationship is established; nothing links thiamine intake to a racetam effect.
Docosahexaenoic acid is the dominant long-chain polyunsaturated fatty acid in neuronal membrane phospholipids and influences membrane fluidity, which is the physical environment every membrane receptor sits in. Stacks pair it with racetams on that structural reasoning, and it also serves as a lipid vehicle for a lipophilic compound. No trial tests the pair.
Nothing specific on file for Aniracetam. Match the label to the daily amount above, and tell your doctor what you take.
Not medical advice. Show the label to your pharmacist.What Aniracetam actually does.
Aniracetam is N-anisoyl-2-pyrrolidinone, a member of the racetam family built on the 2-pyrrolidinone ring shared with piracetam. The anisoyl group added to that ring is what makes it lipophilic where piracetam is water-soluble.
Because it is lipophilic and poorly water-soluble, absorption depends on dietary lipid being present, so an empty-stomach dose and a dose with a fatty meal are not equivalent exposures.
Cholinergic facilitation reported for racetams draws on the acetylcholine pool, whose synthesis requires both choline and acetyl-CoA. That dual requirement is why choline donors and acetyl donors are the standard companions in this class.
AMPA and NMDA receptors are the two ionotropic glutamate receptor families at the same synapses: AMPA carries the fast depolarising current, NMDA opens only once that depolarisation relieves its magnesium block. A compound acting on one therefore changes the conditions for the other.
Where Aniracetam comes from.
This is a lab-made molecule. Chemists start from a small ring compound shared by the whole racetam family and bolt on an aromatic piece, which makes it dissolve in fat rather than water. Since nothing is harvested, quality comes down to purity testing and what solvent traces are left behind.
Chemically synthesised. The molecule is identical to the one a plant or an animal makes, and building it deliberately means a known purity, a fixed dose and no crop contaminants. For several nutrients this is the only route that reaches a usable amount.
The pyrrolidinone ring is the shared racetam scaffold, industrially available from gamma-butyrolactone chemistry. The aromatic half comes from a para-methoxybenzoyl (anisoyl) reagent.
The ring nitrogen of 2-pyrrolidinone is acylated with the anisoyl group to form the amide bond that defines aniracetam. This step is what distinguishes it from the other racetams, which carry different substituents on the same ring.
The crude solid is recrystallised from solvent to remove unreacted starting material, the corresponding acid, and process solvents. Residual solvent limits are the specification that matters most here.
Identity is confirmed spectroscopically and purity by HPLC against a reference standard, with heavy metals and residual solvents tested. There is no botanical marker to standardise against; assay purity is the whole specification.
Packed as bulk powder, encapsulated dry, or dispersed in a lipid carrier.
The forms it comes in.
Problems people have reported.
Read this carefully. These are 95 voluntary, unverified reactions reported to the FDA (openFDA). The number mostly reflects how popular Aniracetam is, not how risky it is. A report is not proof Aniracetam caused anything. It is a signal of what to watch for, nothing more.
Source: openFDA adverse-event reports. Voluntary reporting, not an incidence rate.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.